Baylor College of Medicine: Capsida Receives FDA IND Clearance for Its First-in-class, IV-Administered Gene Therapy for STXBP1-developmental and Epileptic Encephalopathy
May 24, 2025
May 24, 2025
HOUSTON, Texas, May 24 -- The Baylor College of Medicine issued the following news:
* * *
Capsida receives FDA IND Clearance for its first-in-class, IV-administered gene therapy for STXBP1-developmental and epileptic encephalopathy
Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital will participate in Capsida Biotherapeutics' multicenter clinical trial to study an inves . . .
* * *
Capsida receives FDA IND Clearance for its first-in-class, IV-administered gene therapy for STXBP1-developmental and epileptic encephalopathy
Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital will participate in Capsida Biotherapeutics' multicenter clinical trial to study an inves . . .